Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Journal of Clinical Pathology

• Publication date

  2011-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1309/AJCPXTZSKBRIP07WPMID 22095371
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.

  2011cited by this paper
• Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17

  2011cited by this paper
• Is it too soon to start reporting HER2 genetic heterogeneity?

  2010cited by this paper
• Proposal of modification for the definition of genetic heterogeneity in HER2 testing in breast cancer.

  2010cited by this paper
• Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.

  2010cited by this paper
• Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis

  2009cited by this paper
• Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.

  2009cited by this paper
• Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

  2009cited by this paper
• Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

  2009cited by this paper
• Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer

  2009cited by this paper
• HER2 status and benefit from adjuvant trastuzumab in breast cancer.

  2008cited by this paper
• Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?

  2008cited by this paper
• Fluorescence In Situ Hybridization (FISH) as Primary Methodology for the Assessment of HER2 Status in Adenocarcinoma of the Breast: A Single Institution Experience

  2007cited by this paper
• Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.

  2005cited by this paper
• T E C H N I C a L a D V a N C E Open Access Clinical Array-based Karyotyping of Breast Cancer with Equivocal Her2 Status Resolves Gene Copy Number and Reveals Chromosome 17 Complexity

  year unknowncited by this paper

• Challenges and Prospects in HER2-Positive Breast Cancer-Targeted Therapy.

  2025cites this paper
• A Comprehensive Analysis of HER2 status Heterogeneity Using Matched Samples among Potential Beneficiaries of Trastuzumab Deruxtecan Therapy in Non-Small Cell Lung Cancer.

  2025cites this paper
• Analysis of HER2 Heterogeneity at the Protein and Gene Levels in Endometrial Cancer: Refining HER2 Reporting and HER2-directed Therapies.

  2025cites this paper
• Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma

  2025cites this paper
• High HER2 Intratumoral Heterogeneity Is Resistant to Anti-HER2 Neoadjuvant Chemotherapy in Early Stage and Locally Advanced HER2-Positive Breast Cancer

  2025cites this paper
• Breast cancer metastasis to the nasopharynx: A case report

  2025cites this paper
• Not All HER2-Positive Breast Cancers Are the Same: Intratumoral Heterogeneity, Low-Level HER2 Amplification, and Their Impact on Neoadjuvant Therapy Response.

  2025cites this paper
• Breast Cancer Biopsies With Group 2 and Group 4 Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization Results Should Have Repeated Testing on Excision.

  2025cites this paper
• Clinicopathologic and molecular characterization of low-grade, early-stage, and HER2-positive invasive breast carcinoma.

  2025cites this paper
• Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

  2024cites this paper
• Liquid biopsy-based technologies: a promising tool for biomarker identification in her2-low breast cancer patients for improved therapeutic outcomes

  2024cites this paper
• HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment

  2024cites this paper
• Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring

  2024cites this paper
• Prediction of HER2 Status Based on Deep Learning in H&E-Stained Histopathology Images of Bladder Cancer

  2024cites this paper
• Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer

  2024cites this paper
• High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer

  2024cites this paper
• HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls

  2024cites this paper
• Machine learning‐based model constructed from ultrasound radiomics and clinical features for predicting HER2 status in breast cancer patients with indeterminate (2+) immunohistochemical results

  2024cites this paper
• Ultrasound-based radiomics model for predicting molecular biomarkers in breast cancer

  2023cites this paper
• HER2-Low Breast Cancer: Current Landscape and Future Prospects

  2023cites this paper
• HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent high-grade endometrial cancer.

  2023cites this paper
• A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer

  2023influential citation
• HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept

  2023cites this paper
• HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?

  2023cites this paper
• Deep learning radiomics model based on breast ultrasound video to predict HER2 expression status

  2023cites this paper
• Emerging Landscape of Targeted Therapy of Breast Cancers With Low HER2 Protein Expression.

  2023cites this paper
• Single HER2‐positive tumor cells are detected in initially HER2‐negative breast carcinomas using the DEPArrayTM–HER2‐FISH workflow Lisa Grüntkemeier1 · Aditi Khurana2 · Farideh Zamaniyan Bischoff3 · Oliver Hoffmann1 · Rainer Kimmig1 · Mathew Moore2 · Philip Cotter2 · Sabine Kasimir‐Bauer1

  2022cites this paper
• Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

  2022cites this paper
• Novel markers in breast pathology

  2022cites this paper
• HER2-Low Breast Cancer: Novel Detections and Treatment Advances.

  2022cites this paper
• Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies

  2022cites this paper
• The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review

  2022cites this paper
• UK recommendations for HER2 assessment in breast cancer: an update

  2022cites this paper
• Update on prognostic and predictive biomarkers of breast cancer.

  2022cites this paper
• Unusual Patterns of HER2 Expression in Breast Cancer: Insights and Perspectives

  2022cites this paper
• Chemokines in Triple-Negative Breast Cancer Heterogeneity: New Challenges for Clinical Implications.

  2022cites this paper
• Avoiding “False Positive” and “False Negative” Immunohistochemical Results in Breast Pathology

  2022cites this paper
• Update on HER2 expression in breast cancer

  2022cites this paper
• Updates on breast biomarkers

  2022cites this paper
• Characteristics of HER2-Positive Breast Cancer according to HER2 2+/ Low or 3+/High Classification by Immunohistochemistry Assay: Study of 205 Cases Treated in a Single Center

  2021cites this paper
• HER2-Low Breast Cancers New Opportunities and challenges

  2021cites this paper
• HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity

  2021cites this paper
• Targeting HER2 heterogeneity in breast cancer.

  2021cites this paper
• HER2-Low Breast Cancers.

  2021cites this paper
• The Prognostic Impact of HER2 Genetic and Protein Expression in Pancreatic Carcinoma—HER2 Protein and Gene in Pancreatic Cancer

  2021cites this paper
• Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors.

  2020cites this paper
• Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation‐dependent probe amplification: a descriptive study

  2020cites this paper
• Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond.

  2020cites this paper
• The assessment of HER2 status and its clinical implication in breast cancer

  2020cites this paper
• HER2 Testing in Endometrial Serous Carcinoma.

  2020cites this paper
• HER2 Testing in Endometrial Serous Carcinoma Time for Standardized Pathology Practice to Meet the Clinical Demand

  2020cites this paper
• Pathologic Features and Clinical Implications of Breast Cancer With HER2 Intratumoral Genetic Heterogeneity.

  2019cites this paper
• Pathology of Senegalese breast cancers

  2019cites this paper
• Invasive Ductal Carcinoma (NOS) of the Breast

  2019cites this paper
• Studying the value of prognostic and predictive biomarkers in breast cancer pathology

  2018cites this paper
• Comparison of HER2 testing among laboratories: Our experience with review cases retested at Moffitt Cancer Center in a two‐year period

  2018cites this paper
• FGFR1 amplification and FGFR gene fusion in resected squamous cell carcinoma of the lung

  2018cites this paper
• 56 – HER2-Positive Breast Cancer

  2018cites this paper
• Breast cancer intratumour heterogeneity: current status and clinical implications

  2018cites this paper
• Prognostic implications of HER2 heterogeneity in gastric cancer

  2018cites this paper
• ‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study

  2017cites this paper
• Molecular Testing in Breast Cancer

  2017cites this paper
• Tumor Heterogeneity in Breast Cancer

  2017cites this paper
• Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization

  2017cites this paper
• Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers.

  2017cites this paper
• HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma

  2017cites this paper
• Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue

  2017cites this paper
• HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer

  2017cites this paper
• Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer

  2017cites this paper
• Utility of cytopathological specimens and an automated image analysis for the evaluation of HER2 status and intratumor heterogeneity in breast carcinoma.

  2016cites this paper
• The assessment of HER2 status in breast cancer: the past, the present, and the future

  2016cites this paper
• Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual‐color in situ hybridization

  2016cites this paper
• HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients

  2016cites this paper
• Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment

  2016cites this paper
• Intratumor Heterogeneity in Breast Cancer.

  2016cites this paper
• Mutant Allele Tumor Heterogeneity (MATH) and Head and Neck Squamous Cell Carcinoma

  2015cites this paper
• Molecular heterogeneity in adjacent cells in triple-negative breast cancer

  2015cites this paper
• Detecting intratumoral heterogeneity in routine breast-HER2 testing: low yield of testing multiple blocks.

  2015cites this paper
• Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity

  2015cites this paper
• Expression of Her2/neu receptor in carcinoma gallbladder correlates significantly with advanced tumor stage

  2015cites this paper
• Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.

  2015cites this paper
• Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.

  2014cites this paper
• Invasive Breast Carcinoma

  2014cites this paper
• HER2 in solid tumors: more than 10 years under the microscope; where are we now?

  2014cites this paper
• Heterogeneity and cancer.

  2014cites this paper
• HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

  2014cites this paper
• The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles

  2014cites this paper
• c-myc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia

  2014cites this paper
• Tumor heterogeneity: the Lernaean hydra of oncology?

  2014cites this paper
• Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.

  2014cites this paper
• Cellular heterogeneity and molecular evolution in cancer.

  2013cites this paper
• Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma

  2013cites this paper
• Reply to ‘Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance’

  2013cites this paper
• Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue

  2012cites this paper
• Molecular pathology of breast cancer: what a pathologist needs to know.

  2012cites this paper
• Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas.

  2012cites this paper
• Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

  2012cites this paper
• FGFR1 expression and gene copy numbers in human lung cancer

  2012cites this paper